Iranian Society of Gynecology Oncology


1 Gynecology Department, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Young Researchers and Elites Club, Faculty of Medicine, Islamic Azad University, Yazd, Iran


No Abstract


  1. Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, LortetTieulent J, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66(2):96-114. [DOI:10.3322/caac.21336] [PMID]
  2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-99. [DOI:10.1016/j.vaccine.2012.06.095] [PMID]
  3. Teoh DG, Marriott AE, Isaksson Vogel R, Marriott RT, Lais CW, Downs LJ, et al. Adherence to the 2012 national cervical cancer screening guidelines: a pilot study. Am J Obstet Gynecol. 2015;212(1):62 e1-9. [DOI:10.1016/j.ajog.2014.06.057] [PMID]
  4. Lees BF, Erickson BK, Huh WK. Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol. 2016;214(4):438-43. [DOI:10.1016/j.ajog.2015.10.147] [PMID]
  5. Aboul-Fotouh MEM, Hana IT. Clinical validation of high risk HPV DNA testing versus ThinPrep cytology for primary cervical cancer screening. Middle East Fertil Soc J. 2013;18(2):102-9. [DOI:10.1016/j.mefs.2012.12.001]
  6. Karimi-Zarchi M, Zanbagh L, Shafii A, Taghipour-Zahir S, Teimoori S, Yazdian-Anari P. Comparison of Pap Smear and Colposcopy in Screening for Cervical Cancer in Patients with Secondary Immunodeficiency. Electron Physician. 2015;7(7):1542-8. [DOI:10.19082/1542] [PMID]